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Background: Coronary artery bypass grafting (CABG) on cardiopulmonary bypass (CBP) is associated with
significant morbidity and mortality. In high-risk patients, doomed for reoperation the adverse effects of CBP may be
more striking. We evaluated the results of reoperative CABG (redo-CABG) by either off-pump (OPCAB) or on-pump
(ONCAB). Clinical endpoints were perioperative myocardial infarction, mortality, survival and as the most striking
difference between prior studies the quality of life (QoL).
Methods: We performed a prospective, non-randomized assessment for patients who underwent redo-CABG by
redo-OPCAB (n = 40) or redo-ONCAB (n = 40) at our institution between January 2007 and December 2010. For
evaluation of QoL the SF-36 health survey was used with self-administered assessment.
Results: During follow-up 37 of 40 patients were alive in the redo-OPCAB group versus 32 of 40 patients in the
redo-ONCAB group (p < 0.05). The shorter operation time, less blood loss, fewer perioperative myocardial
infarctions, the higher rate of totally arterial revascularisation and shorter intensive care stay were the significantly
beneficial differences for patients in the redo-OPCAB group (p < 0.05). The 3-year survival rate was higher in the
redo-OPCAB group with 81 ± 12% versus 63 ± 9%in the redo-ONCAB group. The quality of life survey did not reveal
any significant differences between both groups.
Conclusion: In conclusion, with our present retrospective study, we could demonstrate the safety and efficacy of
the redo-OPCAB technique with even higher 3-year survival rate. Both techniques seem to have similar impact on
the outcome of patients.Background
Coronary artery bypass grafting (CABG) of high-risk
patients with the use of the cardiopulmonary bypass
(CPB) may be associated with deleterious effects, inclu-
ding the diffuse systemic inflammatory response, global
myocardial ischemia and the risks of aortic manipulation
[1,2]. These may contribute to the morbidity associated
with CABG [3]. Off-pump coronary artery bypass
grafting (OPCAB) has emerged as an alternative tech-
nique to on-pump coronary artery bypass grafting
(ONCAB) allowing coronary revascularization without
the risk associated with CPB [4]. The OPCAB approach* Correspondence: engin.usta@gmx.de
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reproduction in any medium, provided the orhas been shown to reduce the overall systemic inflam-
matory response, including cytokine-mediated response
[5,6]. It also avoids physiologic derangement to the
heart caused by cardioplegic arrest as shown by reduced
troponin T release [5,7].
As operative techniques evolve and survival after car-
diac operations improves, the number of patients who
have repeat sternotomy inevitably continues to increase.
When coronary reoperation is necessary, the presence of
a patent left internal mammary artery (LIMA) graft to
the left anterior descending artery (LAD) creates specific
risks, including the possibility of intraoperative injury to
the graft and potential difficulties with myocardial pro-
tection [8,9]. Conventional redo-ONCAB after previous
CABG represents a surgical challenge due to the poten-
tial for injury to patent coronary grafts, aorta or rightd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tality and morbidity [10-12]. The mortality rate after
redo-ONCAB is reported to be more than three times
higher than that of primary CABG [12]. Injury to a patent
LIMA-LAD graft at reoperation can have catastrophic
outcomes.
In this study, we retrospectively analyzed our results of
redo CABG either as redo-OPCAB or redo-ONCAB in
non-randomized patients. The endpoints evaluated for
the study were: in-hospital mortality, early mortality, late
mortality, follow-up survival, hospital stay, intensive care
stay, rate of totally arterial revascularization, incidence
of perioperative myocardial infarction, perioperative
stroke, major adverse cardiac events, postoperative renal
failure, postoperative complications and transfusion of
blood or blood products. Additionally, we explored the
endpoints actual health status and quality of life (QoL).
The recurrence of cardiac disorders like dyspnea
according NYHA III and angina pectoris according CCS
III were also evaluated. The results should clarify if
clinical outcomes differ depending on the chosen ope-
ration for this selected high-risk patient group.
Methods
Patient selection
The study protocol followed the Declaration of Helsinki
and was approved by the Ethics and Research Commit-
tee of the Robert-Bosch-Hospital in Stuttgart Germany
an academic training hospital of the Tuebingen University.
Between January 2007 and December 2010 80 patients
underwent reoperative CABG (redo-CABG) in the
Departement for Cardiac- and Vascular Surgery of the
Robert-Bosch-Hospital in Stuttgart Germany. A consecutiveTable 1 Presents patients demographic data





Body mass index (kg/m2) 28
Left-ventricular ejection fraction (%) 52
Comorbidities
Diabetes mellitus (%) 43
Hypertensive disease (%)
Smoking history (%) 65
Previous CABG (months ago) 140
Previous coronary grafts (n=) 3
Euroscore (logistic) 23
Creatinine (mg/dl) 1.2 ±
OPCAB, off-pump coronary artery bypass grafting; ONCAB, on-pump coronary arter
class, Canadian Cardiovascular Society classification; Data are expressed as mean ±prospective series of n = 40 patients were operated off-
pump (redo-OPCAB group) and n = 40 patients on-
pump (redo-ONCAB group). A randomization which
procedure is chosen for the patient was not applied.
Data analysis indicate that in the beginning more
patients were operated on-pump resulting in different
follow-up times and that patients with renal insuffi-
ciency were operated preferentially off-pump (Table 1).
After obtaining institutional review board approval,
medical records, including operative notes, were retro-
spectively reviewed for all patients who underwent
redo-CABG in the above mentioned period.
We sent each patient enrolled into this study a self-
administered questionnaire about the actual health situation.
Additionally, each patient received a self-administered Short
Form Health Survey (SF36) [13] giving information
about the patient´s physical and mental status of the
last four weeks. Nevertheless, inclusion criteria were
living patients and those who completed the question-
naire and SF36 survey.
Clinical endpoints
Patients of the redo-OPCAB and redo-ONCAB group
were analysed by comparing various preoperative, peri-
operative and postoperative variables (Tables 1, 2, 3 and 4).
Endpoints for the study were: in-hospital mortality, late
mortality, blood loss, transfusion of blood or blood pro-
ducts, rate of totally arterial revascularization, perioperative
myocardial infarction, length of intensive care stay, length
of hospital stay, cumulative survival and composite event-
free survival (Table 1).
In all enrolled patients the operations were performed
by five staff surgeons, who are involved in our minimal40) Redo-ONCAB (n = 40) p-value
± 10 71 ± 9 0.12
32 36 0.07
8 4 0.07
± 4 29 ± 4 0.91
± 12 53 ± 18 0.97
± 50 39 ± 49 0.59
100 96 ± 9 1.00
± 48 61 ± 5 0.73
± 74 139 ± 69 0.80
± 1 3 ± 1 0.05
± 19 22 ± 17 0.66
1.2 1.0 ± 0.21 0.65
y bypass grafting; NYHA class, New York Heart Association classification; CCS
standard deviation.
Table 2 Procedural details, the postoperative course and information about the occurrence of perioperative
myocardial infarction are depicted
Variable Redo-OPCAB (n = 40) Redo-ONCAB (n = 40) p-value
Operation time (min) 195 ± 69 248 ± 40 0.01
Total arterial revascularization (n=) 28 12 0.01
Bilateral internal mammary artery (BIMA) (n=) 0.28 ± 0.45 0.30 ± 0.47 0.484
Radial artery 0.15 ± 0.43 0.19 ± 0.40 0.821
Saphenic vein graft (n=) 0.3 ± 0.48 0.85 ± 0.72 0.007
Single grafts (n=) 1.05 ± 0.55 1.52 ± 1.16 0.06
Sequential grafts (n=) 0.52 ± 0.55 0.62 ± 0.86 0.952
Total blood loss (ml) 540 ± 494 867 ± 619 0.02
Transfusion of blood and/or derivatives (n=) 11 9 0.53
Postoperative ventilation (hours) 7 ± 8 9 ± 10 0.08
Intensive care stay (days) 3 ± 2 5 ± 3 0.01
In-hospital stay (days) 15 ± 10 13 ± 5 0.88
Cardiac ischemia markers (12 hours postop)
CK (U/l) 335 ± 341 709 ± 746 0.01
CK-MB (U/l) 38 ± 45 30 ± 37 0.78
Troponin 0.5 ± 0.5 5.3 ± 11 0.01
LDH 208 ± 89 323 ± 135 0.01
Postoperative major cardiac adverse effects (n=) 3 4 0.78
Impaired wound healing (%) 7 ± 3 4 ± 2 0.15
OPCAB, off-pump coronary artery bypass grafting; ONCAB, on-pump coronary artery bypass grafting; CK, creatine kinase; CK-MB, creatine kinase isoenzyme form
MB; LDH, lactate dehydrogenase. Data are expressed as mean ± standard deviation. Significant values are printed in bold type.
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similar numbers of CABG but with different experience
and learning curves regarding redo-OPCAB.Anesthesiological and haemodynamic management
The procedures were performed under general endo-
tracheal anaesthesia with a regular single-lumen intubation.
The patients were positioned on a bair huggerW mattress
(Arizant Healthcare Inc., Eden Prairie, MN 55344, USA) in
the operation room.Table 3 The actual follow-up and various forms of mortality a
Variable Redo-OPCAB (n
Actual follow-up (months) 22
Alive (n=)
In hospital mortality (n=)
Early mortality (n=)
Late mortality (n=)
Dyspnea according NYHA III (n=)
Angina pectoris according CCS III (n=)
Recent coronary reintervention (n=)
Composite events
OPCAB, off-pump coronary artery bypass grafting; ONCAB, on-pump coronary arter
values are bold typed.Hemodynamic monitoring comprised of six-channel
electrocardiography with ST-segment trend analysis and
radial arterial pressure. Monitoring included regular
continuous pulse oxymetry.
In the redo-OPCAB group the FloTrac sensor and
VigileoTM monitor (Edwards Lifesciences, Irvine, CA,
USA) were utilized for minimal-invasively hemodynamic
monitoring. This system calculates cardiac output by
analyzing arterial pressure waveform [14,15]. In the
Redo-ONCAB group we used pulmonary artery cathe-
ters to measure cardiac output by thermodilutionre presented
= 40) Redo-ONCAB(n = 40) p-value









y bypass grafting. Data are expressed as mean ± standard deviation. Significant
Table 4 Features the quality of life or SF-36 health survey in the redo-OPCAB and redo-ONCAB patients
Variable Redo-OPCAB (n = 40) Redo-ONCAB (n = 40) p-value
Physical performance 58 ± 30 55 ± 30 0.65
Role performance 48 ± 43 49 ± 45 0.97
Bodily pain 65 ± 35 53 ± 30 0.15
General health 56 ± 23 51 ± 24 0.58
Vitality 48 ± 25 47 ± 26 0.98
Social functioning 74 ± 26 69 ± 31 0.67
Role emotionale 70 ± 39 76 ± 36 0.66
Mental health 77 ± 20 68 ± 18 0.06
OPCAB, off-pump coronary artery bypass grafting; ONCAB, on-pump coronary artery bypass grafting; Data are presented as mean ± standard deviation. Significant
values are depicted in bold type.
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sure, central venous pressure, mean pulmonary pressure,
pulmonary capillary wedge pressure, cardiac index, car-
diac output, and systemic vascular resistance. Arterial
blood gases and activated clotting time (ACT) were
monitored every 30 minutes.
During the operation a transesophageal echocardiog-
raphy (TEE) (CX50 CompactXtreme, Philips, Germany)
was utilized for assessment of myocardial wall irregularities
and unclear related walve pathologies especially in the
Redo-ONCAB group if weaning of CPB was protracted.
The anticoagulation regimen in the Redo-OPCAB
group and Redo-ONCAB group differed. Intravenous
heparin was applicated with a dose of 150 IU/kg body
weight in the redo-OPCAB group, less than in the redo-
ONCAB group with a dose of 300 IU/kg body prior to
the institution of CPB to accomplish an activated coagu-
lation time of greater than 400 sec. This different
anticoagulation regimen, with lower heparin dose in the
off-pump group derives from our clinical routine and is
in accordance to data from literature [16] as cannulation
of the aorta and right atrium is not necessary in the off-
pump technique. Finally, the total amount of heparin
was reversed with protamine after completion of the
anastomoses.
Surgical technique for redo-OPCAB
After median sternotomy the left internal mammary artery
(LIMA) and or the right internal mammary artery (RIMA)
were harvested by standard technique using hemoclips in
a scletonizing fashion if not being utilized in the prior op-
eration. In case of open graft vessels those were mobilized
in their proximal segments. The other conduits (saphe-
nous veins and radial artery) were harvested simultan-
eously using endoscopic vessel harvesting (EVH) (Maquet
Inc., Rastatt, Germany). We used CTS OPCAB access
platform and stabilizer (Cardiothoracic Systems, Cuper-
tino, CA, USA) or Hercules Universal Stabilizer Arm™
with stabilizer (Estech Company, San Ramon, CA, USA)
to stabilize the target coronary vessel. In the Redo-OPCAB group we always used intracoronary shunts
(Baxter AnastaFLO intravascular shunt, Irvine, CA,
USA) for anastomosis. In most cases, the left anterior
descending coronary artery was the first coronary artery
to be grafted. The vessels on the lateral and posterior
wall were grafted later. However, the sequence of
grafting was individualized for a particular patient, de-
pending on the severity of the lesions in different cor-
onary arteries and patient’s hemodynamics. Both the
left anterior descending and right coronary arteries
could be grafted without much displacement of the
heart. For exposure of the circumflex and right coro-
nary vessels pericardial traction sutures were used to
pull the heart vertically. In most cases the pleurae were
not opened. A vertical pericardiotomy was performed
to herniate the heart to the right chest under the
sternum. Other maneuvers such as the Trendelenburg
position and tilting the table were performed as
required. Inotropic agents were used when necessary
during surgery. We used 8–0 Seralon polyamide suture
(Serag-Wiessner KG, Naila, Germany) for the distal
anastomosis and 6–0 for the proximal anastomosis.
Surgical technique for redo-ONCAB
Conventional coronary artery bypass procedures were
performed using standard CPB, which was established
using ascending aortic and two-stage venous cannula-
tion. An open extracorporeal circuit was used, which
was identical in each patient and consisted of a mem-
brane oxygenator, arterial filter and crystalloid priming.
The LIMA and RIMA were harvested in a scelotonizing
fashion if not being utilized in the prior operation. Open
LIMA or RIMA in-situ graft vessels were mobilized in
their proximal segments for the later cross-clamping
during cardioplegia. The radial artery and saphenous
vein were usually harvested utilizing endoscopic vessel
harvesting equipment (EVH) (Maquet Inc., Rastatt,
Germany). After instituting CPB the aorta and open
LIMA or RIMA in-situ grafts were cross-clamped and
the procedure was performed on an cardioplegic arrested
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was allowed to drift as was usually between 32-34°C.
Antegrade Brettschneider´s crystalloid cardioplegia (1500 ml)
was used for myocardial protection (Dr. Franz Köhler
Chemie Inc., Bensheim, Germany). Cardioplegia was re-
peated if myocardial contractions occurred. Rewarming was
initiated during completion of the last peripheral anasto-
mosis. Reperfusion was performed with whole blood by
declamping of the aorta and open LIMA or RIMA in-situ
grafts. Reperfusion time was defined till the end of CPB.
Graft vessel selection
Routinely, all patients underwent preoperative clinical
and non-invasive angiological examinations of the radial
artery diameters (luminal diameter) by the attending car-
diovascular surgeon. Further a normal Allen’s test on the
chosen side was compulsory. Radial arteries with im-
mense atherosclerotic changes or luminal diameter less
than 2 mm were excluded prior to harvesting. The
saphenous vein was scanned additionally and was
doomed as a graft if the luminal diameter was at least 3
mm. Duplex ultrasound was performed by the cardio-
vascular surgeon with a Siemens ACUSON Antares™
ultrasound system equipped with a VF13-5 transducer
probe (Siemens AG, Erlangen, Germany). A 2-D linear
electronic probe at 7.0 MHz, pulse wave Doppler at 5.0
MHz and color Doppler at 5.0 MHz were used. The
angle of the emitted Doppler ultrasound wave from the
probe was adjusted to 60° to achieve the Doppler signal
of the strongest intensity. The internal diameter of the
vessel was measured using M-mode technique. When-
ever feasible we favourized harvesting arterial grafts if
not utilized in the past. Due to the prospective non-
randomized character of this study the majority of the
redo-ONCAB patients were operated in the first half of
the observation period resulting in lesser utilization of
arterial grafts in comparison to the redo-OPCAB pa-
tients. Further each patient was examined by coronary
angiograpy assassing the viability of the native coronary
arteries and the graft vessels preoperatively.
Quality control and assessment criteria
Graft patency and bypass fow rates were analyzed intra-
operatively using a handheld 2, 3 or 4 mm transit-time
flowprobe connected to a MediStim VeriQ System
(MediStim ASA, Oslo, Norway). Postoperative ECG
(electrocardiogram), serial samples of creatine kinase
(CK), CK-MB, cardiac troponin I (cTnI) and after 2009
high-sensitive cardiac troponin I (hs cTnI) were deter-
mined every 6 h up to 48 h in any patient. Myocardial
infarction was defined as either Q-wave in the postope-
rative ECG or an increase in the CK-MB enzyme fraction
above 10% and simultaneous increase of cTnI of more than
10 ng/ml or hs cTnI of more than 100 ng/ml. An earlypostoperative control angiography was not recommended,
except for patients with postoperative myocardial infarc-
tion suspected (patients with postoperative angina and
increase of troponin I and CK-MB levels).Postoperative patient management
Patients of both groups were transferred to the intensive
care unit (ICU) and ventilation was kept till reaching a
stabile haemodynamic situation. Usually, patients were
weaned from ventilation as early as possible. On the next
day, we transferred the patients to our intermediate care
unit (IMC) for further surveying. We transferred the
patients on postoperative day (POD) two our regular
cardiovascular service till discharge from hospital.Postoperative follow-up and SF-36 health survey
We aimed to assess the surveillance and quality of life of
the operated patients by sending them self-administered
questionnaires by mail. Usually, we sent them a cover
letter, the SF-36 questionnaire, a self-administered ques-
tionnaire on angina pectoris and dyspnea and a stamped
self-addressed return envelope. We instructed our pa-
tients to give information about their health situation of
the last four weeks.
The questionnaires consisted of two parts. Part one
comprised items about the actual health situation and
the recurrence of cardiac disorders like angina pectoris
and dyspnea with necessary interventions in the follow-
up period. The assessment of angina pectoris and dys-
pnea by self-administered questionnaire was considered
valid in view of the very satisfactory agreement between
the coding of the patient and medical coding (New York
Heart Association (NYHA) and Canadian Cardiovascular
Society classification (CCS) [17] for angina pectoris and
for dyspnea [18].
Part two, the SF-36 health survey is one of the most
extensive standardized, self-administered, generic ques-
tionnaires for measuring both the physical and mental
health of a patient [5,13,19]. It was developed to assess
the functional status and well-being of patients. SF-36
consists of 36 questions in eight areas: physical function-
ing (physical limitations in performance of daily living),
role-physical (problems encountered with daily activities
or work as a result of physical health), bodily pain (over-
all pain severity), general health perception (overall gen-
eral health), vitality (frequency of feeling full of energy
vs. tired), social functioning (performing normal social
activities or not), role-emotional (problems with work or
daily activities as a result of emotional problems) and
mental health (degree of nervousness or depression).
Higher values on the transformed 0–100 scale for each
health domain indicate better health status.
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Patients medical-records were surveyed respectively the in-
cidence of parameters like mortality peri- or postoperatively.
The mortality in this period was defined as in-hospital mor-
tality. Death occurring until 30 days postoperatively was de-
fined as early and after this period as late mortality.
Like in the preceding section mentioned the question-
naires consisted of two parts. Part one comprised items
about the actual health situation and the recurrence of
cardiac disorders like dyspnea according NYHA III and
angina pectoris according CCS III with necessary coron-
ary interventions in the follow-up period. If the ques-
tionnaires were not sent back after one month patients
were telephoned or the family physician was contacted.
In addition, patient medical-records were studied if
during the last hospital stay MACCE (Major Adverse
Cardiac and Cerebrovascular Events) occurred. Dyspnea
according NYHA III, angina pectoris according CCS III,
MACCE, in-hospital mortality, early and late mortality
occurring during the hospital-stay and follow-up were
defined as a censored event.
Later Kaplan-Meier analysis and Cox proportional
hazards models were used to calculate hazard ratios
(HR) and 95% confidence intervals (CI), with adjust-
ments for baseline patient and disease characteristics.
Survival analyses consisted of two parts. Part one was
cumulative survival with the subgroup 3-year survival.
The censored event was defined as death occurring as in-
hospital mortality, early and late mortality during follow-
up. Part two was the assessment of composite event-free
survival with subgroup 3-year survival. The censored
event was defined as dyspnea according NYHA III, angina
pectoris according CCS III, MACCE, recent coronary
intervention, in-hospital mortality, early and late mortality
occurring during the hospital-stay and follow-up.
Statistical analysis
Values were expressed as mean ± standard deviation.
Continuous data were analyzed using the Wilcoxon´s
rank test. The Kaplan–Meier method was used to ana-
lyse cumulative survival, 3-year survival and freedom
from events (death, myocardial infarction and repeat
intervention, angina, dyspnea and MACCE). The log
rank test was used to compare the survival and freedom
from events between redo-OPCAB and redo-ONCAB.
Probability values (P) of less than 0.05 were considered
significant. Generally we presented the exact P-value. Stat-
istical analysis was performed using the JMP program
(version 9, SAS Institute, Cary, North Carolina, USA).
Results
Evaluation of patients characteristics
The patients preoperative demographic data did not dif-
fer significantly (p < 0.05) between the redo-OPCAB andredo-ONCAB groups (Table 1). Both groups revealed
similar preoperative cardiac function and similar preva-
lence of comorbidities.
Procedural details and intraoperative data
There were significant (p < 0.05) differences in the redo-
OPCAB und redo-ONCAB groups. The shorter ope-
ration time, more use of arterial grafts, and less blood
loss were the significant differences in the redo-OPCAB
group (Table 2). No significant difference existed for the
transfusion of blood or derivatives between both groups
(Table 2).
Postoperative results and clinical outcome
Patients in the redo-OPCAB group differed significantly
(p < 0.05) with shorter intensive care stay, lower CK,
Troponin and LDH expression. No significant difference
existed for the incidence of postoperative major cardiac
adverse effects, impaired wound healing and in-hospital
mortality (Table 2).
Analysis of intraoperative patients characteristics
The groups significantly differed in the operation time
(redo-OPCAB, 195 ± 69, and redo-ONCAB, 248 ± 40 min;
p = 0.01) (Table 2). Another significant difference was the
rate of totally arterial revascularization redo-OPCAB, 28,
and redo-ONCAB, 12 patients; p = 0.02) (Table 2). Al-
though not significant, slightly more patients undergoing
redo-ONCAB had more single coronary bypass grafts
(redo-OPCAB, 1.05 ± 0.55, and redo-ONCAB, 1.52 ± 1.16;
p = 0.06.
Comparison of postoperative data
The groups significantly differed in the amount of post-
operative total blood loss (redo-OPCAB, 540 ± 494, and
redo-ONCAB, 867 ± 619 ml; p = 0.02) (Table 2). There
was no significance in the category transfusion of blood
and/or derivatives (redo-OPCAB, 11 patients, and redo-
ONCAB, 9 patients; p = 0.53) (Table 2).
Further significant differences were the intensive care stay
(redo-OPCAB, 1.92 ± 1.71, and redo-ONCAB, 2.93 ± 2.37;
p = 0.01). Although not significant, slightly more patients
undergoing redo-ONCAB were ventilated longer (redo-
OPCAB, 7.3 ± 8.2, and redo-ONCAB, 8.6 ± 5.5 hours;
p = 0.08) (Table 2).
Cardiac ischemia and MACCE
Considering the perioperative myocardial infarction pa-
rameters, there are significant differences in both groups
with higher rate of infarction in the redo-ONCAB group
(Table 3). Creatine kinase (CK) and troponin I levels were
higher in the redo-ONCAB group (redo-OPCAB, 334.5 ±
341.4, and redo-ONCAB, 707.4 ± 745.7 U/l; p = 0.01) and
Figure 2 Kaplan-Meier analyses of composite event-free
survival. OPCAB, off-pump coronary artery bypass grafting; ONCAB,
on-pump coronary artery bypass grafting. On the X-axis the follow-
up in months and on the Y-axis the fraction survival are given. The
censored event was defined as death occurring as in-hospital
mortality, early and late mortality during follow-up. The censored
event was defined as dyspnea according NYHA III, angina pectoris
according CCS III, MACCE, recent coronary intervention, in-hospital
mortality, early and late mortality occurring during the hospital-stay
and follow-up.
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11.18 ng/ml; p = 0.01), respectively (Table 3).
The only significant difference in the category of
MACCE was the occurrence of postoperative brain or-
ganic disease, with significantly higher frequency in the
redo-ONCAB group (redo-OPCAB, 0%, and redo-
ONCAB, 15 ± 4% of patients; p = 0.02).
Cumulative survival
The Kaplan–Meier analyses are depicted in Figure 1. Al-
though not significant, 3-year survival was 81 ± 11% in
the redo-OPCAB and 63 ± 9% in the redo-ONCAB
group (p = 0.08). In the log rank test with a Chi square
of 5.88 the cumulative survival curves were significantly
different (p = 0.01).
The hazard ratio was 2.99 with a 95% CI (confidence
interval) of ratio 0.78–5.42.
Composite event-free survival
The Kaplan–Meier analyses are presented in Figure 2.
Although not significant, 3-year composite event free
survival was 62 ± 8% in the redo-OPCAB and 68 ± 8% in
the redo-ONCAB group (p = 0.87). In the log rank test
with a Chi square of 0.36 the cumulative survival curves
were not significantly different (p = 0.55).
The hazard ratio was 1.32 with a 95% CI of ratio 0.54–
3.21.
Quality of life assessment and SF-36 health survey
evaluation
The redo-OPCAB and redo-ONCAB groups were eval-
uated on the basis of eight categories according to the
SF-36 health survey (Figure 3). The categories were phys-
ical performance (PP), role performance (RP), bodily pain
(BP), general health (GH), vitality (VT), social function-
ing (SF), role emotionale (RE) and mental health (MH).Figure 1 Kaplan-Meier analyses of cumulative survival. OPCAB,
off-pump coronary artery bypass grafting; ONCAB, on-pump
coronary artery bypass grafting. On the X-axis the follow-up in
months and on the Y-axis the fraction survival are given. The
censored event is death occurring during follow-up.There were no significant differences among both
groups. Although not significant, slightly more patients
undergoing redo-OPCAB had higher scores in mental
health (redo-OPCAB, 76.82 ± 19.91, and redo-ONCAB,
68.31 ± 17.34; p = 0.06) (Figure 3).
Discussion
In an attempt to avoid the deleterious effects of cardiopul-
monary bypass (CPB), off-pump coronary artery bypass
grafting (OPCAB) has gained broader acceptance since
the last decade. Nevertheless conventional non-beating
heart on-pump CABG is still the standard technique used
in coronary artery surgery in many institutions. Complica-
tions in relation to this technique are due to the release of
inflammatory mediators, the use of cardioplegia, aortic
cross clamping and hypothermia [20]. Blood contact with
the artificial surfaces of the CPB circuit produces a well-
documented diffuse inflammatory response that affects
multiple organ systems. Virtually all detrimental effects of
this diffuse inflammatory response increase with large
duration of CPB.
OPCAB technique was introduced to avoid such com-
plications. Despite its efficiency and safety over conven-
tional CPB, the technique was criticized by many
investigators regarding completeness of myocardial re-
vascularization, graft patency and long term results. Co-
ronary artery bypass grafting on the beating heart is a
more demanding procedure than conventional CABG. It
is more difficult in terms of technical skills and requires
more attention to the surgeon and the anaesthesiologist.
Many authors [3,21,22] have reported series of OPCAB.
Although they have presented excellent mortality rates,
concern has been raised over a decrement in graft
Figure 3 Figure 1 presents the evaluation of the quality of life or SF-36 health survey in the redo-OPCAB and redo-ONCAB patients.
For this survey eight major categories were evaluated and the transformed scores were depicted on a 100 point score scale. PP, physical
performance; RP, role performance; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotionale; MH, mental health;
OPCAB, off-pump coronary artery bypass grafting; CABG, coronary artery bypass grafting; Data are expressed as mean ± standard deviation.
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this technique is the hemodynamic deterioration which
can occur during manipulation of the heart during sur-
gery, which entails urgent transfer to conventional CPB
[24,25].
Considering the above mentioned data, we have mean-
while established the OPCAB technique for coronary
revascularization as our standard technique. Nowadays
we perform at least more than 90% of primary coronary
revascularizations by OPCAB (not yet published data).
In the cases of redo coronary revascularisations we
achieved similar rates utilizing OPCAB (not yet pub-
lished data). Therefore our presented data contains a
significantly difference in regard of the postoperative
follow-up period in the redo-OPCAB and redo-ONCAB
group. The explanation for this circumstance is that in
the second half of the observation period most of the
redo coronary revascularisations were performed by
redo-OPCAB. As in the first half of the observation
period more single saphenic vein grafts were anasto-
mosed in the second half the trend was towards total
arterial revascularization with sequential anastomosis.
This may be the result of the maturation process orcompleting the learning curve and changes of staff sur-
geons with different experience and learning curves re-
garding redo-OPCAB. Despite of the referred drawbacks
of the OPCAB technique [25], we had never to convert
redo-OPCAB to redo-ONCAB in our study population.
Interestingly, the number of previous coronary grafts de-
termined preoperatively was higher in our redo-ONCAB
group. Therefore the higher number of distal anasto-
mosis just reflects the higher occlusion rate of previous
coronary grafts in the redo-ONCAB group. Neverthe-
less, we have considered complete revascularization to
be the “gold standard” for coronary bypass operations
irrespective of the surgeon’s choice of incision or use of
CPB, and still hold this belief.
The present study reports clinical outcomes and quality
of life surveillance in 69 patients undergoing redo coron-
ary revascularization either by redo-OPCAB or redo-
ONCAB. After prior review of the appropriate literature
we could not find any study investigating the quality of life
of these highly selective patients group in such an extent.
Our study aims to clarify if both procedures differ at the
endpoints mortality, transfusion requirements, periopera-
tive myocardial infarction, inotropic drug support, major
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of cardiac disorders. Considering our study population
with a mean Euroscore (logistic) around 23, it is justified
to declare them as high risk patients. To our knowledge, it
is unique and different from published data to include
particularly the high risk patients in such a study [26,27].
In the present retrospective comparison, we demonstrate
the safety and efficacy of redo-OPCAB. Redo-OPCAB pa-
tients, although generally having similar preoperative risk
factors like on-pump redo-ONCAB patients, enjoy a
decreased incidence of perioperative myocardial infarction,
postoperative organic brain disease, and decisively a de-
creased mortality. Considering our data, we can claim that
redo-OPCAB patients have shorter operation times, less
postoperative blood loss and shorter stay on IMCU. Al-
though not significant, postoperative ventilation tends to
be shorter in the redo-OPCAB group. Our presented data
is in analogy to those of the referred literature [26-31].
In contrast to the above presented data, the evaluation
of the SF-36 health survey [13] did not reveal signifi-
cant differences among the redo-OPCAB and redo-
ONCAB groups.
Limitations of the study
We want to address few limitations of our present
study. The study comprises, in comparison to the re-
ferred data high-risk patients undergoing coronary redo
revascularisation. Both groups differ in the follow-up
period. The limitations of our study include the pro-
spective single-institution methodology being not a
randomized clinical trial. Further limitations are the
small number of patients, the inability to conduct a re-
liable multivariate analysis of predictor variables of late
mortality due to the small number of patients with the
index event.
Conclusions
In conclusion, with our present retrospective study, we
could confirm the safety and efficacy of both surgical
procedures of redo-CABG, with better results for the
redo-OPCAB technique. Nevertheless in this era where
the use of multivessel coronary angioplasty is extensively
employed the therapeutic option of redo-CABG,
tendencially declining, should not be ignored in our clin-
ical routine. Our future effort will be to perform a
double-blinded randomized prospective study to gain
more information and to clarify which technique is su-
perior in this selective patient group especially in regard
to the quality of life.
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